George C Eckert Ii

Array ( [id] => 17556280 [patent_doc_number] => 11312963 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-04-26 [patent_title] => Compositions and methods for inhibiting TIGIT gene expression [patent_app_type] => utility [patent_app_number] => 16/655484 [patent_app_country] => US [patent_app_date] => 2019-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 11 [patent_no_of_words] => 10545 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16655484 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18518711 [patent_doc_number] => 11708594 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-07-25 [patent_title] => Reconfigurable DNA nano-tweezer [patent_app_type] => utility [patent_app_number] => 16/653235 [patent_app_country] => US [patent_app_date] => 2019-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 19 [patent_no_of_words] => 9376 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16653235 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15436165 [patent_doc_number] => 20200032266 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-30 [patent_title] => Compositions for Selection of Aptamers [patent_app_type] => utility [patent_app_number] => 16/599970 [patent_app_country] => US [patent_app_date] => 2019-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14780 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16599970 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17250033 [patent_doc_number] => 11185501 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-11-30 [patent_title] => Method and composition for targeted delivery of therapeutic agents [patent_app_type] => utility [patent_app_number] => 16/599978 [patent_app_country] => US [patent_app_date] => 2019-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 14 [patent_no_of_words] => 16532 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16599978 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17496538 [patent_doc_number] => 11285222 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-03-29 [patent_title] => Compositions and methods for delivery of agents [patent_app_type] => utility [patent_app_number] => 16/599661 [patent_app_country] => US [patent_app_date] => 2019-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 112 [patent_figures_cnt] => 159 [patent_no_of_words] => 104014 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 112 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16599661 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17336398 [patent_doc_number] => 20220002729 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-06 [patent_title] => COMPOSITION COMPRISING APTAMER AS ACTIVE INGREDIENT FOR TREATMENT AND PREVENTION OF DEGENERATIVE BRAIN DISEASE [patent_app_type] => utility [patent_app_number] => 17/292710 [patent_app_country] => US [patent_app_date] => 2019-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3857 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17292710 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17178645 [patent_doc_number] => 11155880 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2021-10-26 [patent_title] => Methods of measuring C19MC miRNA in a post-natal tissue and uses thereof [patent_app_type] => utility [patent_app_number] => 16/594930 [patent_app_country] => US [patent_app_date] => 2019-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 8501 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 140 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16594930 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19105807 [patent_doc_number] => 11958888 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-04-16 [patent_title] => Micro-dystrophins and related methods of use [patent_app_type] => utility [patent_app_number] => 16/593833 [patent_app_country] => US [patent_app_date] => 2019-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 36 [patent_no_of_words] => 22789 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16593833 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16283996 [patent_doc_number] => 20200277598 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-03 [patent_title] => Peptide Oligonucleotide Conjugates [patent_app_type] => utility [patent_app_number] => 16/593615 [patent_app_country] => US [patent_app_date] => 2019-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35455 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16593615 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15708501 [patent_doc_number] => 20200101016 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-02 [patent_title] => COMPOSITIONS AND METHODS FOR PRODUCING EXOSOME LOADED THERAPEUTICS FOR TREATING CARDIOVASCULAR DISEASE [patent_app_type] => utility [patent_app_number] => 16/591483 [patent_app_country] => US [patent_app_date] => 2019-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7064 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16591483 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15711595 [patent_doc_number] => 20200102563 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-02 [patent_title] => EXOSOME LOADED THERAPEUTICS FOR TREATING SICKLE CELL DISEASE [patent_app_type] => utility [patent_app_number] => 16/591502 [patent_app_country] => US [patent_app_date] => 2019-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7481 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16591502 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17923044 [patent_doc_number] => 11466279 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-10-11 [patent_title] => Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters [patent_app_type] => utility [patent_app_number] => 16/591422 [patent_app_country] => US [patent_app_date] => 2019-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 31 [patent_no_of_words] => 50851 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16591422 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15496293 [patent_doc_number] => 20200048335 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-13 [patent_title] => NOVEL USE OF REGULATORY T CELL-SPECIFIC SURFACE PROTEIN LRIG-1 [patent_app_type] => utility [patent_app_number] => 16/591023 [patent_app_country] => US [patent_app_date] => 2019-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7483 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16591023 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17336390 [patent_doc_number] => 20220002721 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-06 [patent_title] => ANTISENSE RNA TARGETING PMP22 FOR THE TREATMENT OF CHARCOT-MARIE-TOOTH 1A DISEASE [patent_app_type] => utility [patent_app_number] => 17/279206 [patent_app_country] => US [patent_app_date] => 2019-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13724 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17279206 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16072971 [patent_doc_number] => 20200190472 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-18 [patent_title] => AGENTS AND METHODS TO ELICIT ANTI-TUMOR IMMUNE RESPONSE [patent_app_type] => utility [patent_app_number] => 16/579583 [patent_app_country] => US [patent_app_date] => 2019-09-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30731 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16579583 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15799915 [patent_doc_number] => 20200123100 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-23 [patent_title] => COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS [patent_app_type] => utility [patent_app_number] => 16/555045 [patent_app_country] => US [patent_app_date] => 2019-08-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 70158 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16555045 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17665520 [patent_doc_number] => 11359201 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-06-14 [patent_title] => Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro [patent_app_type] => utility [patent_app_number] => 16/552478 [patent_app_country] => US [patent_app_date] => 2019-08-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 55 [patent_figures_cnt] => 67 [patent_no_of_words] => 46565 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 236 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16552478 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15619357 [patent_doc_number] => 20200080083 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-12 [patent_title] => OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF [patent_app_type] => utility [patent_app_number] => 16/551503 [patent_app_country] => US [patent_app_date] => 2019-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 188103 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16551503 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15324751 [patent_doc_number] => 20200002705 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-02 [patent_title] => METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF GLYCOLATE OXIDASE (HAO1) BY DOUBLE-STRANDED RNA [patent_app_type] => utility [patent_app_number] => 16/545149 [patent_app_country] => US [patent_app_date] => 2019-08-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 73795 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16545149 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17118737 [patent_doc_number] => 11129846 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-09-28 [patent_title] => Dosage form for treating severe asthma [patent_app_type] => utility [patent_app_number] => 16/539383 [patent_app_country] => US [patent_app_date] => 2019-08-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 12 [patent_no_of_words] => 12381 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16539383 [rel_patent_id] =>[rel_patent_doc_number] =>)